Unicycive Therapeutics' application for approval of oxylanthanum carbonate to treat hyperphosphatemia in kidney disease patients on dialysis has been accepted by the FDA.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia
